Details

Last Funding Type

Post-IPO Equity

Last Funding Money Raised

₪30M

Industries

Biotechnology,Health Care,Life Science

Founded date

Jan 1, 2003

Number Of Employee

51 - 100

Operating Status

Active

Brainsway's patented breakthrough technology launches a new era in brain disorder treatment. A non-invasive, yet highly effective solution, Brainsway can make a difference in the wellbeing and health of millions of patients worldwide.

Brainsway's technology releases millions of patients from a bleak cycle of insufficiently effective treatments and unpleasant side effects. Brainsway's treatment was approved by the FDA for Major Depressive Disorder patients*. The technology is also safe, with no systemic effects or long-term side effects, and highly convenient, requiring only brief daily sessions over a couple of weeks.

Brainsway's technology has already been applied in thousands of cases worldwide in the framework of clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials performed. Brainsway technology is based on a patent registered by the U.S. National Institutes of Health (NIH).

Brainsway is dedicated to research and continuously explores treatments for a variety of brain disorders.